Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
West Pharmaceutical Services heads into its October 29 earnings date with the most constructive analyst backdrop it has seen in months, even as the stock pulled back roughly 1% on the week to $372.64.
The analyst picture is the clearest story here. Barclays raised its target to $440 from $400 this week, maintaining an Overweight rating, one of several upward moves that have clustered since July. Morgan Stanley upgraded the stock to Overweight from Equal-Weight on September 22, lifting its target to $400 from $365. UBS raised its target to $415 in early September. The direction of travel is unusually consistent: every recent change on record has been a raise or an upgrade. The mean Street target now sits at $412.25, about 10.6% above the current price, with the analyst recommendation rank in the 97th percentile of the ORTEX universe. That is not a crowded bull camp so much as a broadly aligned one.
Short positioning tells a quieter story, and rightly so given the modest absolute level. Short interest is 3.1% of the free float, down about 1.1% over the past week, and has been largely flat for the past six weeks rather than building with conviction. Borrow conditions are about as easy as they get: cost to borrow has eased to 0.34%, down 17% on the week, and availability is extraordinarily loose at more than 6,000% of current short interest, meaning there are roughly 69 million shares available against roughly 2.3 million borrowed. The ORTEX short score sits at 35.6, little changed day to day, consistent with a stock where bears have not found a compelling entry. The put/call ratio at 0.73 is a touch below its 20-day average of 0.76 and well within normal ranges. Options traders are not hedging hard into the print.
Valuation remains the one area of tension for bulls. The stock trades at a PE of 38.2, up about 3 points over the past 30 days, and the EV/EBITDA multiple is around 25.4. The EV/EBIT factor score ranks in the 25th percentile, a signal that the premium is real and priced relative to peers. FMR (Fidelity) stands out on the institutional register: its reported holding jumped by more than 2.3 million shares to 5.0% of the company in a filing dated August. BlackRock holds 9.5% and has been adding modestly. Neither position is activist in nature. All 13D/G filings on record are passive Schedule 13G disclosures, and there is no activist on the register. Stakes are as last disclosed around the 5% threshold, and a holder can fall below 5% without a further filing.
The recent insider activity is worth noting, though the framing matters. The Chief HR Officer exercised options and sold shares through September, all under a declared 10b5-1 plan. These are pre-scheduled transactions and carry no signal about the executive's view of the stock's near-term prospects. Net insider activity over 90 days is a sale of roughly 15,700 shares at a net value of about $5.4 million, but the plan-driven nature makes this routine rather than telling.
Earnings on July 23 produced a one-day drop of 8.4% and a five-day decline of 5.3%. The earlier July 30 reading showed a 1% gain on the day. That July 23 reaction is the live data point worth keeping in mind: a print that disappointed sent the stock back sharply, and the stock has since recovered that ground and then some. The pace of analyst target increases since that event suggests the Street has grown more comfortable with the trajectory. With the next print 22 days out, the key question is whether the volume recovery in pharma packaging that underpins those raised targets is showing up in the order book as clearly as the bulls expect.
See the live data behind this article on ORTEX.
Open WST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
